Moderna raises its revenue outlook - but all eyes are on what happens next with its cancer vaccine
Morningstar ·
The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026
Moderna raises its revenue outlook - but all eyes are on what happens next with its experimental cancer vaccine
The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026
2 sources · 3 articles · updated 2026-11-06 15:09 UTC · business
Coverage
Moderna raises its revenue outlook - but all eyes are on what happens next with its experimental cancer vaccine
Morningstar ·
The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026
Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine
MarketWatch ·
The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026